Dr Reddy's Lab launches generic diabetes medication in US market

The company's product is a therapeutic equivalent generic version of Kombiglyze XR tablets, it added

Bs_logoPills, medicine, medication
Photo: Bloomberg
Press Trust of India New Delhi
1 min read Last Updated : Aug 10 2023 | 6:20 PM IST

Dr Reddy's Laboratories on Thursday said it has launched a generic diabetes medication in the US market.

The drug major has launched Saxagliptin and Metformin Hydrochloride extended-release tablets in the US market, the Hyderabad-based company said in a statement.

The company's product is a therapeutic equivalent generic version of Kombiglyze XR tablets, it added.

Dr Reddy's Saxagliptin and Metformin Hydrochloride extended-release tablets are supplied in a strength of 2.5 mg/1000 mg in bottle count of 60 and strengths of 5 mg/500 mg and 5 mg/1000 mg each in bottle counts of 30, the company said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories

  • Over 30 subscriber-only stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :DiabetesDr Reddy's Laboratories LimitedDr Reddy's USFDAMedicines

First Published: Aug 10 2023 | 6:20 PM IST